Dual Diagnosis: Open Access Open Access

Elaboration on Aspects of Future Clinical Diagnosis of the Alzheimers Disease

Anne Saemann^* Department of Biology, University of Barcelona, Spain
^*Correspondence: Anne Saemann, Department of Biology, University of Barcelona, Spain, Email:

Received: 01-Mar-2023, Manuscript No. IPDDOA-23-16645; Editor assigned: 03-Mar-2023, Pre QC No. IPDDOA-23-16645 (PQ); Reviewed: 17-Mar-2023, QC No. IPDDOA-23-16645; Revised: 22-Mar-2023, Manuscript No. IPDDOA-23-16645 (R); Published: 29-Mar-2023, DOI: 10.36648/2472-5048.8.1.03

Introduction

As the leading cause of dementia, Alzheimer’s disease is currently regarded as a global public health threat due to its subtle age-related neurodegeneration. The senile plaques and the p-tau neurofibrillary tangles are its main histological features. Clinically, it is characterized by progressive cognitive decline that reflects the underlying synaptic loss and neurodegeneration. Many drug treatments that target the two pathological hallmarks, a-tau and p-tau, have failed. This is probably because therapy was started at a time when cognitive changes were already obvious. To put it another way, the underlying neuropathological changes have reached a point where these medications are no longer effective in repairing the damage. Because of this, it is critical to get a diagnosis as soon as possible so that treatment can begin as soon as possible so that these changes can be reversed. To this point, the utilization of powerful and useful biomarkers that could give precise finding ideally at a previous period of the sickness is of the quintessence. Until now, a few biomarkers have been laid out that, to an alternate degree, permit scientists and clinicians to assess, analyze, and all the more exceptionally bar other related pathologies.

Description

In this study, we highlighted the most recent advancements in the diagnostic and therapeutic domains as well as a comprehensive review of the data on the currently investigated biomarkers, both pathology-specific and non-specific biomarkers for Alzheimer’s disease. We have concluded with separate remarks and elaboration on aspects of future perspectives. Because of worldwide cooperative exploration endeavors, these have been generally an example of overcoming adversity however there are various constraints that warrant further examination and conversation. First, there is still bias and random variation in biomarker measurements between and within laboratories. Second, the pathology that underlies Alzheimer’s disease is only partially represented by current markers; it is necessary to develop new markers for synaptic dysfunction, microglial activation, and protein aggregates, all of which are frequently associated with plaque and tangle pathology. Third, liquid markers don’t address the anatomic area of any neurotic change; Techniques for high-resolution molecular imaging can be used in conjunction with associated markers from the cerebrospinal fluid.

Conclusion

Acetylcholine esterase inhibitors, for example, are the first therapeutic compounds for treating Alzheimer’s disease, and gamma-and beta-secretase inhibitors, for example, may be developed in the near future. This has requested expanded precision in the conclusion of Promotion and subsequently, among other potential methodologies, demonstrative markers in the cerebrospinal liquid have turned into a quickly developing exploration field. As one might anticipate the compounds to have the greatest potential for being effective, such biomarkers would be especially useful, particularly early in the course of the disease, when correct diagnosis is most difficult. Senile plaques and neurofibrillary tangles containing beta-amyloid and tau proteins are two of the most defining lesions in Alzheimer’s disease brains. Plasma and cerebrospinal fluid are examples of body fluids in which beta and tau proteins are secreted. These cerebrospinal fluid markers perform well enough, according to a growing number of studies, to be used together in the clinical evaluation of dementia patients.